Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsNiketa C Shah, MD
Associate Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor Adjunct
Director,Pediatric Cellular Therapy Program, Pediatric Hematology & Oncology; Director, Pediatric Bone Marrow Transplant Program
Appointments
Pediatric Hematology & Oncology
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Pediatric Bone Marrow Transplant Program
- Pediatric Hematology & Oncology
- Pediatric Hematology & Oncology Program
- Pediatrics
- Yale Cancer Center
Education & Training
- Pediatric Stem Cell Transplant Fellow
- Memorial Sloan Kettering Cancer Center (2010)
- Pediatric Resident
- Newark Beth Israel Medical Center (2009)
- Pediatric Hematology Oncology Fellow
- The Hospital For Sick Children, Toronto (2006)
- MD
- Seth K M School of Postgraduate Medicine and Research, Pediatrics (1997)
- MBBS
- NHL Municipal Medical College (1994)
Research
Copy Link
Overview
Medical Research Interests
Anemia, Sickle Cell; Bone Marrow Failure Disorders; Bone Marrow Transplantation; Hematology; Hematopoietic Stem Cell Transplantation; Pediatrics; Receptors, Chimeric Antigen
ORCID
0000-0001-9992-4921
Research at a Glance
Yale Co-Authors
Frequent collaborators of Niketa C Shah's published research.
Publications Timeline
A big-picture view of Niketa C Shah's research output by year.
Research Interests
Research topics Niketa C Shah is interested in exploring.
Lakshmanan Krishnamurti, MD
Aron Flagg, MD
Jingchen Liang
Yanhong Deng
Daniel Prior, MD
Farzana Pashankar, MD, MRCP, MBBS
30Publications
272Citations
Hematopoietic Stem Cell Transplantation
Anemia, Sickle Cell
Bone Marrow Transplantation
Receptors, Chimeric Antigen
Publications
2026
Long-term follow-up after mixed donor myeloid chimerism at 1 year post transplantation for sickle cell disease
Guilcher G, Dalal S, Suresh T, Yelamali A, Arora J, Aljayyousi H, Bhatia M, Haight A, Khandelwal P, Khoury R, Lafay Q, Mandava M, Nickel R, Ngwube A, Rangarajan H, Shah N, Stenger E, Yelamanchili N, Shenoy S. Long-term follow-up after mixed donor myeloid chimerism at 1 year post transplantation for sickle cell disease. Transplantation And Cellular Therapy 2026 PMID: 41690551, DOI: 10.1016/j.jtct.2026.02.012.Peer-Reviewed Original ResearchCitationsConceptsHematopoietic cell transplantationDonor myeloid chimerismSickle cell diseaseMyeloid chimerismFollow-upPost-HCTConditioning regimensCell diseaseLaboratory markersClinical outcomesHigher chimerismClinical long-term outcomeLifetime surveillanceLong-term follow-upMyeloablative conditioning regimensYears of follow-upTime to follow-upYear post-transplantationMarkers of hemolysisLong-term outcomesNorth American centersSurvivors of hematopoietic cell transplantationLaboratory markers of hemolysisCohort of childrenHemoglobin S percentage
2025
Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy
Shah N, Ngwube A, Suresh T, Sowa A, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Dalal J, Grimley M, Jacobsohn D, Kamani N, Krajewski J, Krishnamurti L, Saini S, Skiles J, Shenoy S. Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplantation And Cellular Therapy 2025, 31: 826.e1-826.e10. PMID: 40543708, DOI: 10.1016/j.jtct.2025.06.015.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGraft-versus-host diseaseChronic graft-versus-host diseaseHematopoietic cell transplantationGraft-versus-host disease prophylaxisGVHD prophylaxisAbatacept groupCell transplantationIncidence of posterior reversible encephalopathy syndromeSeverity of graft-versus-host diseasePresence of graft-versus-host diseasePosterior reversible encephalopathy syndromeAllogeneic hematopoietic cell transplantationSibling donor hematopoietic cell transplantationDonor hematopoietic cell transplantationDonor-derived hematopoiesisImmune reconstitution patternsReduced intensity conditioningEvent-free survivalGraft-versus-hostHost disease prophylaxisReversible encephalopathy syndromeSystemic immune suppressionStem cell transplantationPrimary graft rejectionPediatric stem cell transplantationComparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease
Prior D, Liang J, Deng Y, Shah N, Flagg A, Krishnamurti L. Comparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2025, 31: 594.e1-594.e13. PMID: 40379050, DOI: 10.1016/j.jtct.2025.05.004.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGraft-versus-host diseaseHematopoietic cell transplantationHLA-matched related donorSickle cell diseaseConditioning regimen intensityAnti-thymocyte globulinEFS ratesConditioning regimensRegimen intensityCell transplantationRate of chronic graft-versus-host diseaseRelated donorsChronic graft-versus-host diseaseHematopoietic cell transplantation regimensNon-myeloablative conditioning regimensAllogeneic hematopoietic cell transplantationCell diseaseComparison of regimensMyeloablative conditioning regimensNon-myeloablative conditioningNon-myeloablative regimensSickle cell disease patientsEvent-free survivalGraft-versus-hostAnti-thymocyte
2024
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Krishnamurti L, Liang J, He Z, Deng Y, Nallagatla V, Hamidi R, Flagg A, Shah N. Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease. Blood Advances 2024, 8: 1908-1919. PMID: 38324722, PMCID: PMC11021890, DOI: 10.1182/bloodadvances.2023010749.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHematopoietic cell transplantationSickle cell diseaseVaso-occlusive episodesPainful crisesCell transplantationPost-HCTGraft failureBefore HCTEvent-free survivalOverall survivalPain syndromePatient agePatient-centered outcomesAlternative donorsIncreased riskCell diseaseRisk factorsNatural historyPatientsLogistic regressionPainTransplantationSurvivalAgeAGVHD
2023
Mediport use as an acceptable standard for CAR T cell infusion
Eylon M, Prabhu S, John S, King M, Bhatt D, Curran K, Erickson C, Karras N, Phillips C, Satwani P, Hermiston M, Southworth E, Baumeister S, Talano J, MacMillan M, Rossoff J, Bonifant C, Myers G, Rouce R, Toner K, Driscoll T, Katsanis E, Salzberg D, Schiff D, De Oliveira S, Capitini C, Pacenta H, Pfeiffer T, Shah N, Huynh V, Skiles J, Fraint E, McNerney K, Quigg T, Krueger J, Ligon J, Fabrizio V, Baggott C, Laetsch T, Schultz L. Mediport use as an acceptable standard for CAR T cell infusion. Frontiers In Immunology 2023, 14: 1239132. PMID: 37965315, PMCID: PMC10642031, DOI: 10.3389/fimmu.2023.1239132.Peer-Reviewed Original ResearchAltmetricConceptsCAR T-cell infusionT-cell infusionCell infusionT-cell therapyCell infiltrationClinical practiceChimeric antigen receptor T-cell therapyCAR T-cell therapyCAR-T cell infiltrationCell therapyCell therapy administrationRetrospective cohort studyCentral venous cathetersT cell infiltrationCurrent clinical practiceStandard clinical practiceB-cell malignanciesT cell deliveryEvaluable patientsVenous optionsCohort studyVenous cathetersTherapy administrationPractice patternsCare recommendationsMixed donor chimerism following stem cell transplantation for sickle cell disease
Shah N, Rangarajan H, Ngwube A, Shenoy S. Mixed donor chimerism following stem cell transplantation for sickle cell disease. Current Opinion In Hematology 2023, 30: 187-193. PMID: 37694765, DOI: 10.1097/moh.0000000000000786.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsHematopoietic stem cell transplantationDonor/recipient chimerismStem cell transplantationSickle cell diseasePost-HCTRecipient chimerismDonor chimerismCell transplantationCell diseaseDisease controlDonor-derived erythropoiesisHCT conditioning regimensMixed donor chimerismSerial chimerism analysesRecent clinical trialsDonor erythropoiesisConditioning regimensHigh morbidityCurative interventionsClinical trialsSuccessful engraftmentSCD manifestationsMyeloid cellsHb S traitChimerism analysisCan defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?
Shah N, Shenoy S. Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation? The Lancet Haematology 2023, 10: e309-e311. PMID: 37001535, DOI: 10.1016/s2352-3026(23)00065-0.Peer-Reviewed Original ResearchCitationsAltmetricRole of abatacept in the prevention of graft-versus-host disease: current perspectives
Ngwube A, Rangarajan H, Shah N. Role of abatacept in the prevention of graft-versus-host disease: current perspectives. Therapeutic Advances In Hematology 2023, 14: 20406207231152644. PMID: 36845849, PMCID: PMC9943961, DOI: 10.1177/20406207231152644.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricConceptsHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantChronic GVHDGVHD prophylaxisDonor hematopoietic stem cell transplantSteroid-refractory chronic GVHDPrevention of graftSevere acute GVHDStem cell transplantAcute GVHDGVHD preventionHLA disparityHost diseaseGraft rejectionHSCT settingUnrelated donorsCalcineurin inhibitorsCell transplantNonmalignant disordersAlternative donorsMouse modelClinical practiceGVHDProphylaxisLimited reports
2022
The Use of Extracorporeal Membrane Oxygenation as a Bridge to Bone Marrow Transplantation in a Patient With High-risk Acute Myeloid Leukemia
Nader M, Bonde P, Massaro S, Giuliano J, Shah N. The Use of Extracorporeal Membrane Oxygenation as a Bridge to Bone Marrow Transplantation in a Patient With High-risk Acute Myeloid Leukemia. Journal Of Pediatric Hematology/Oncology 2022, 45: 18-20. PMID: 36219701, DOI: 10.1097/mph.0000000000002567.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHigh-risk acute myeloid leukemiaExtracorporeal membrane oxygenationAcute myeloid leukemiaMyeloid leukemiaMembrane oxygenationAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationVenoarterial extracorporeal membrane oxygenationTransplantation 2 monthsStem cell transplantationBone marrow transplantationMultiorgan dysfunction syndromeExtracorporeal life supportMarrow transplantationCell transplantationPatient selectionSeptic shockDysfunction syndromeRisk stratificationCardiogenic shockBiventricular failureTreatment protocolsCirculatory supportYounger ageMultidisciplinary approachHematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium
Rangarajan HG, Stanek JR, Abdel-Azim H, Modi A, Haight A, McKinney CM, McKeone DJ, Buchbinder DK, Katsanis E, Abusin GA, Ahmed I, Law J, Silva JG, Mallhi KK, Burroughs LM, Shah N, Shaw PJ, Greiner R, Shenoy S, Pulsipher MA, Abu-Arja R. Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium. Transplantation And Cellular Therapy 2022, 28: 329.e1-329.e9. PMID: 35288346, DOI: 10.1016/j.jtct.2022.03.007.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHematopoietic cell transplantationEvent-free survivalCongenital dyserythropoietic anemiaCell transplantationAllogeneic hematopoietic cell transplantationSecond hematopoietic cell transplantationDyserythropoietic anemiaSole curative optionVeno-occlusive diseaseRetrospective multicenter studyMajority of patientsOutcome of childrenUmbilical cord bloodCDA type IICDA type IAcute graftAggressive chelationChronic GVHDHost diseaseCumulative incidenceCurative optionGraft failureMedian durationNonmyeloablative regimensOverall survival
News
Copy Link
News
- July 26, 2023
2022-23 Department of Pediatrics Faculty Awards
- May 04, 2023
42 Yale Pediatricians Recognized by Connecticut Magazine's 2023 “Top Doctors” List
- May 01, 2023
Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Smilow Cancer Hospital and Yale Cancer Center physicians
- October 12, 2022
Pediatric Bone Marrow Transplant Reunion
Get In Touch
Copy Link
Contacts
Email